Peptide Encyclopedia / Cardiogen
EncyclopediaCardiogen is a short Khavinson-family peptide, usually cited as the tripeptide Ala-Glu-Asp, marketed as a heart-targeted bioregulator. Its proposed action on cardiac gene expression stays unproven, rests on limited Russian preclinical work, and it is unapproved in the US. Educational, not medical advice.
| Category | Longevity / Anti-aging |
| Regulatory status | Not FDA-approved; research chemical / gray-market in the US. |
A short synthetic peptide (commonly cited as the tripeptide Ala-Glu-Asp) from the Khavinson bioregulator family, marketed as a heart/myocardium-targeted agent. Proposed (unproven) mechanism is tissue-specific modulation of gene expression supporting cardiac cells.
uncertain / limited human pharmacokinetic data; presumed rapid clearance for a tripeptide but no rigorous human PK exists.
Not FDA-approved; research chemical / gray-market in the US. Not an FDA-approved drug; sold within Russia in the bioregulator/supplement context only.
Human safety data are minimal and largely Russian-sourced. Self-administration of an agent marketed for cardiac tissue is of particular concern given the absence of controlled human safety data. Gray-market purity/identity unverified.
Weak/limited evidence base: predominantly Russian (Khavinson group) preclinical work, with essentially no independent Western human replication.
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. Cardiogen may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
